Emerging PARP inhibitors for treating breast cancer.

Emerging PARP inhibitors for treating breast cancer. Expert Opin Emerg Drugs. 2018 Sep 25;: Authors: Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M Abstract INTRODUCTION: Some breast cancers harbor defects in DNA repair pathways, including BRCA1 and BRCA2 mutations, leading to a genomic instability. Compromised DNA-damage repair response is found in 11 to 42% of triple negative breast cancers, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Several PARP inhibitors have currently reached early phase trials with studies on going in the adjuvant, neoadjuvant and metastatic setting. Area covered: Here, we review completed and ongoing trials with PARP inhibitors as well as their mechanisms of activity and acquired resistance. Expert opinion: PARP inhibitors show promising results in breast cancer. However, several issues are raised including the identification of biomarkers to predict treatment response and strategies to counteract emerging resistance. PMID: 30251552 [PubMed - as supplied by publisher]
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Related Links:

ConclusionOur study contributes to the descriptive prevalence of some known risk factors in Indian breast cancer patients.
Source: The Journal of Obstetrics and Gynecology of India - Category: OBGYN Source Type: research
1.5 billion: that’s the number, in dollars, Forbes put for Proteus’ valuation last year. Dubbed as a healthcare unicorn, the startup even raised over $500 million in venture capital. It made headlines for developing the first-ever FDA-approved digital pill, one equipped with an ingestible and trackable sensor to monitor treatment compliance.  Researchers even proved the technology’s worth. In 2019, an independent study investigated the Proteus’ digital pill. They found it to be accurate, and even improved adherence of tuberculosis patients using oral pills equipped with Proteus’ s...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence Future of Medicine Future of Pharma Genomics AI cancer IBM google deepmind theranos Watson fail digital pill proteus deus ex machina tech giants finances otsuka Nightingale Source Type: blogs
Epstein Barr virus (EBV) is a cosmopolitan oncogenic virus, infecting about 90% of the world's population and it is associated to tumors originating from both epithelia and hematopoietic cells. Transmission of the virus is mainly through oral secretions; however, transmission through organ transplantation and blood transfusion has been reported. In order to evade immune recognition, EBV establishes latent infection in B lymphocytes where it expresses limited sets of proteins called EBV transcription programs (ETPs), including six nuclear antigens (EBNAs), three latent membrane proteins (LMP), and untranslated RNA called EB...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Condition:   Triple Negative Breast Cancer Intervention:   Drug: oral etoposide + anlotinib Sponsor:   Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
nse J Abstract Daridorexant is a dual orexin receptor antagonist in clinical development for the treatment of insomnia. Breast-cancer resistant protein (BCRP) is an efflux pump expressed in intestinal epithelium and hepatocytes, contributing to the absorption, distribution, and elimination of drugs and endogenous compounds.In vitro, daridorexant inhibits BCRP with an IC50 of 3.0 μM. The BCRP substrate rosuvastatin is a cholesterol-lowering drug, recommended for clinical drug-drug interaction (DDI) studies. In order to exclude an inhibitory effect of daridorexant on BCRP, this single-centre, open-label, two-trea...
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
Liz Satterfield has a ritual for every time she returns home after leaving the house. Diagnosed with metastatic breast cancer in 2016, the Kirkland, Washington resident recently learned that the cancer that had spread to her brain in 2018 was still growing. Throughout the pandemic, she’s had to visit the hospital at least once every three weeks, often more frequently, for treatments to control her disease. “I have a pair of shoes in a paper bag that I keep in the trunk of my car or a rack in the garage. I only wear those shoes when I’m going in to get treatment,” she says. “When I come home, I...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
ConclusionsIn our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ER α. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859.
Source: EJNMMI Research - Category: Radiology Source Type: research
Abstract Increased frequency of cancer in recent years and its impact on different physical, mental, and social dimensions of human life have turned it to a major problem of this century. We can group cancer according to the type of cells they start from viz. skin cancer, colon cancer, bladder cancer, breast cancer, prostate cancer, kidney cancer oral cancer etc. Among this, breast cancer is one of the most prevalent type of malignant neoplasm within women with more than one million new cases per year. In the recent years, with the help of targeted drug delivery system, several attempts were made to restrict the d...
Source: Current Diabetes Reviews - Category: Endocrinology Authors: Tags: Curr Diabetes Rev Source Type: research
AbstractIntroductionAntiprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations identified during clinical studies, further development was halted. Evaluation of antiprogestin pharmacology and pharmacokinetic data suggested that liver enzyme elevations might be related to off-target or metabolic effects ...
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
ConclusionsThe risk of PDDIs in patients receiving OAAs increases, particularly with the concomitant use of PKIs with gastrointestinal or psychiatric drugs and endocrine agents with antidepressants. Considering the potential risk of chronic concomitant use of these drug classes in outpatients, healthcare professionals should be made aware of the potential interactions.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Gastroschisis Repair | Neoadjuvant Therapy | Oral Cancer | Study